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PIDs are rare disorders resulting from
impaired function(s) in the immune sys-
tem. Most are caused by mutations
affecting proteins with key roles in
the development or function of cells
of the immune system.
Being mostly diseases of genetic ori-
gin, it is difficult to cure PIDs, and life-
long immunoglobulin (Ig) replacement
therapy (periodical intravenous or sub-
cutaneos administration of nonspecific
plasma-derived antibodies from
healthy donors) is the only treatment
for many patients with PIDs.
Alterations in epigenetic regulators
(mainly controlling DNA methylation, his-Primary immunodeficiencies (PIDs) are immune disorders resulting from
defects in genes involved in immune regulation, and manifesting as an
increased susceptibility to infections, autoimmunity, and cancer. However,
the molecular basis of some prevalent entities remains poorly understood.
Epigenetic control is essential for immune functions, and epigenetic alterations
have been identified in different PIDs, including syndromes such as immuno-
deficiency-centromeric-instability-facial-anomalies, Kabuki, or Wolf–Hirsch-
horn, among others. Although the epigenetic changes may differ among
these PIDs, the reversibility of epigenetic modifications suggests that they
might become potential therapeutic targets. Here, we review recent mechanis-
tic advances in our understanding of epigenetic alterations associated with
certain PIDs, propose that a fully epigenetically driven mechanism might
underlie some PIDs, and discuss the possible prophylactic and therapeutic
implications.tone modifications, or chromatin remo-
deling) are increasingly being described
for PIDs. Since epigenetic marks, unlike
DNA mutations, can be pharmacologi-
cally reprogrammed, an understanding
of how aberrant epigenetic patterns are
initiated and maintained in PIDs might
help us devise approaches to restore
normal immune function.
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cesar.cobaleda@csic.es (C. Cobaleda).The Heterogeneous Nature of Human Immunodeficiencies
Human primary immunodeficiencies (PIDs) constitute a varied group of more than 350 immune
disorders that cause an increased susceptibility to infections, autoimmunity, and cancer, linked to
significant morbidity and mortality [1]. PIDs can appear clinically isolated or as a component of
more complex multiorganic syndromes (syndromic immunodeficiencies). Most PIDs aregenetic in
origin, and new genes affected in PIDs are being described in increasing numbers [2]. Genetically
unraveled PIDs are caused by either spontaneous or hereditary mutations affecting proteins with
key roles in the development or function of cells of the immune system. The molecular pathways
altered by these mutations can be manifold, and the clinical spectrum of PIDs is heterogeneous,
with pathological consequences that can affect both immune and non-immune systems, ranging
from just a reduced response to pathogens to problems such as autoimmunity and cancer [3].
Since they mainly have a genetic origin, the only definitive treatment for severe PIDs is hemato-
poietic stem cell transplantation (HSCT, see Glossary), which is a successful procedure, but
still not exempt from significant morbidity and mortality. Autologous infusion of gene therapy-
corrected precursors is another curative procedure in a growing number of cases. Otherwise,
lifelong immunoglobulin (Ig) replacement therapy (periodical intravenous or subcutaneos admin-
istration of nonspecific plasma-derived antibodies from healthy donors) is the main treatment for
many patients with PID [4], together with prophylactic use of antibiotics, immunosupressants for
autoimmune and inflammatory complications, and, more exceptionally, immunomodulating
agents, such as interferon (IFN)-g or other cytokines [5].
Although many different immune cell types can be affected in PIDs, more than half of patients
with PID present with Ig deficiencies [1,2] and, in the clinic, almost 90% of these patients haveTrends in Immunology, January 2019, Vol. 40, No. 1 https://doi.org/10.1016/j.it.2018.11.005 49
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Glossary
Choanae: posterior nasal apertures;
two openings at the back of the
nasal passage between the nasal
cavity and throat.
Class switch recombination
(CSR): immunoglobulin class
switching or isotype switching;
mechanism that changes the isotype
of Ig produced by a given B cell,
such as from IgM to IgG, or IgA or
IgE. In this process, the variable
region of the Ig does not change
and, therefore, the antibody retains
affinity for the same antigen, but the
change in the constant regions
allows its interaction with different
effector molecules. CSR occurs in
GCs requiring AID protein function.
Common variable
immunodeficiency (CVID):
heterogeneous PID characterized by:
(i) at least one of five criteria:
increased susceptibility to infection;
autoimmune manifestations;
granulomatous disease; unexplained
polyclonal lymphoproliferation; or
affected family member with antibody
deficiency; and (ii) with a marked
decrease in IgG, IgA, or, at least a
poor antibody response to vaccines,
or low switched memory B cells.
Contiguous gene syndrome
(CGS): clinical phenotype caused by
deletion of several consecutive genes
in close proximity to one another on
the chromosome. The phenotype of
these patients is the result of a
combination of individual defects of
deleted genes, plus the potential
synergic effects of their losses.
Genotype/phenotype correlation:
assessed relationship between a
given genotype and its
corresponding (usually pathological)
phenotype, to identify the relationshipdefects in B cell differentiation [3], with disorders such as congenital agammaglobulinemias,
class switch-recombination (CSR) or hyper-IgM (HIGM) defects, genetically defined and
undefined common variable immunodeficiency (CVID), and selective IgA deficiency (IgAD)
or IgG subclass deficiency. B cell development (reviewed in [6,7]) is a tightly regulated process
requiring the coordinated action of extrinsic signals (cytokines, ligands, antigens, and inter-
acting T and dendritic cells), intrinsic factors (epigenetic regulators, transcription factors, and
DNA recombination-activating proteins) and basic cellular processes (cellular proliferation and
DNA repair). Therefore, interference with any of these elements can result in defective B cell
function and compromised antibody production. In recent years, alterations in genes involved
in the epigenetic control of cellular identity and function (Boxes 1 and 2 ; Figure 1, Key Figure)
have been associated with several PIDs, including syndromes such as immunodeficiency-
centromeric-instability-facial-anomalies 1 (ICF1), Kabuki, Wolf–Hirschhorn (WHS), Schimke
Immuno-Osseous Dysplasia (SIOD), Wiedemann–Steiner (WS), CHARGE, Kleefstra, Roifman,
and INO80 loss-of-function (Figure 1). By analogy, the well-established role of epigenetic
alterations in other pathologies has become an active area of investigation, as in the case of
cancer [8,9], complementing the previous mutation-centric interpretation of malignancies.
Furthermore, due to their largely reversible nature, epigenetic modifications are quickly
becoming crucial putative therapeutic targets in cancer and other diseases [10]. Here, we
review recent advances in our understanding of the various epigenetic molecular mecha-
nisms that have been shown to have a role in the aforementioned human PIDs. We also
discuss the concept that other PID-causing mutations not previously known to be associated
with epigenetic modifications may also act as epigenetic modifiers and, consequently,
deregulated epigenetics might constitute one of the causes contributing to certain molecu-
larly undefined PIDs. These findings lead us to propose that a fully epigenetically driven
mechanism might contribute to explaining the origin of certain subsets of human immuno-
deficiencies. Finally, we discuss the implications of these findings relevant to our understand-
ing of the origin and evolution of PIDs, as well as the potential for future prophylactic and
therapeutic interventions.
Human Immunodeficiencies with Known Genetic Defects in Genes Encoding
Epigenetic Modifiers
Immune development is tightly controlled at the epigenetic level [6,7]. Indeed, there are many
recent examples of immune or hematopoietic malfunctions in experimental knockout mice
lacking known epigenetic regulators (Box 3), confirming the immunoregulatory role of these
genes. However, here we focus on the molecular alterations that have already been identified in
patients with PID (Figure 1), although it is likely that many of the findings in animals will be
correlated with human diseases in the future.that correlates a particular
abnormality in a patient with a certain
mutation.
Germinal center (GC): specific sites
within the spleen and lymph nodes
where mature B cells proliferate,
differentiate, and mutate their
antibody genes in the processes of
CSR and SHM.
Graft versus host disease (GvHD):
arises after the reception of
transplanted tissue from a genetically
different individual (such as in
HSCTs), where the donor’s T cells in
the graft recognize the recipient (the
host) as a foreign antigen and attack
Box 1. Basic Molecular Epigenetic Mechanisms
Epigenetics is the group of processes that control the establishment, maintenance, and inheritance of gene expression
patterns without altering the germline DNA sequence [109]. They guarantee that the right genes are expressed at the
right time in the right cellular context and in a heritable pattern, and, therefore, are responsible for establishing cell
identity and function throughout development. At the molecular level, they are based on different chemical marks on
DNA and histones (acetylation, methylation, phosphorylation, etc.), which can be added or removed by different
enzymes, and can subsequently be ‘read’ by various effector proteins [110,111]. The combination of these marks
generates a code that determines the windows and expression of genes (see Box 2).
Extreme complexity arises with the existence of active crosstalk between epigenetic marks themselves, and with
transcription factors and other cellular structural proteins: changes in one epigenetic mark are usually followed by a
cascade of other epigenetic alterations, often laterally propagated within chromatin.
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the recipient’s host tissues, creating
severe organ damage.
Hematopoietic stem cell
transplantation (HSCT): medical
procedure that involves transplanting
HSCs, either from a healthy,
compatible donor, or as cells from
the same patient (autologous); for
example, cells that have been
treated to correct a particular defect.
Injected cells will engraft in the bone
marrow and produce new, healthy
blood cells. HSCT can be used to
replace diseased bone marrow that
is malfunctioning and producing
aberrant or insufficient blood cells.
Hyper IgM syndrome (HIGM): type
of PID. People with HIGM cannot
switch (see ‘CSR’) from the
production of IgM antibodies to
antibodies of the IgG, IgA or IgE
types: they have decreased
concentrations of IgG and IgA but
normal or elevated IgM in their blood.
B cells require active interaction with
T cells to carry out CSR. HIGM can
result from genetic defects interfering
in the correct interaction between T
and B cells.
Immunological memory: the
capacity of the immune system to
respond more rapidly and specifically
when the organism is attacked again
(challenged) by a previously
encountered pathogen; mainly
mediated by memory B and memory
T cells.
Memory B cells: see
‘immunological memory’.
Somatic hypermutation (SHM):
programmed process of mutation
where point mutations accumulate in
the variable regions of
immunoglobulin genes at high rates.
SHM occurs in GCs, where newly
mutated Igs are positively selected to
increase their affinity and specificity
for antigen. SHM is initiated by the
AID protein.
Transitional B cells: an
intermediate differentiation stage in B
cell development situated between
immature B cells in the bone marrow
and mature B cells in the spleen.
Box 2. Overview of Molecular Epigenetic Regulators
Important molecular epigenetic regulators include:
 DNA methylation: chemical modification adding a methyl mark at the position 5 of cytosine in 50CpG30 dinucleotides.
The methyl group is transferred by DNA-methyltransferases (DNMTs), either de novo (DNMT3A and DNMT3B,
establishing DNA methylation patterns) or via maintenance DNMTs (DNMT1, following the replication fork to copy
DNA methylation patterns on the daughter strand). CpG islands are genome regions enriched in CpG dinucleotides,
concentrating near gene promoters, where CpG cytosines that are unmethylated are usually associated with active
gene transcription, whereas CpG island methylation, usually leads to gene repression. Correct CpG methylation
patterns are essential for controlling gene expression during development and differentiation. Cytosine methylation
can also be reverted mainly by proteins of the ten-eleven-translocation (TET1-3) family.
 Histone modifications: DNA is wound around histones to form chromatin; the different forms of histones can undergo
many types of post-transcriptional modifications (methylation, acetylation, phosphorylation, ubiquitination, SUMOy-
lation, etc.) affecting different residues (Lys, Ser, Thr, and Arg) in several positions along polypeptide histone chains,
to different degrees (e.g., mono-, di-, and trimethylation). Most of these marks can also be removed by demethy-
lases, deacetylases, and so on. Crosstalk between histone marks can occur within the same histone or among
different ones and, therefore, the final functional outcome of histone modifications depends on the combination of all
marks (forming a ‘histone code’).
 Chromatin remodelers: in eukaryotes, there are four families of ATP-dependent chromatin remodelers (SWI/SNF,
ISWI, NURD/Mi-2/CHD, and INO80/SWR1), capable of shaping chromatin architecture by relocating nucleosomes
and creating nucleosome-free regions in DNA, allowing the access of the transcription machinery.
 Noncoding RNAs are functional RNA molecules, not translated into proteins. Several structural and functional types
exist, constituting a heterogeneous group, including molecules capable of regulating gene expression. They can
participate, among other epigenetic functions, in chromatin remodeling and transcriptional and post-transcriptional
regulation.Immunodeficiencies due to Alterations in DNA Methylation Patterns
DNMT3B in Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
ICF1 syndrome (OMIM 242860) is an autosomal recessive disorder in which patients present with
immunodeficiency, facial anomalies, and instability of the pericentromeric heterochromatin of
chromosomes 1, 9, and 16. The immunodeficiency is usually severe and can lead to premature
death during childhood due to infections [11]. Patients normally present a decrease in serum IgG
levels, and reduced numbers of B or T cells are also possible. The gene responsible for ICF1
encodes DNA de novo methyltransferase 3B (DNMT3B; Box 2 and Figure 1) [12,13]. A full
knockout of Dnmt3b catalytic activity is perinatal lethal in mice [14], suggesting that mutations
in patients with ICF1 are more likely to impair than to completely abolish enzymatic activity (Box 3).
This is supported by the fact that mice carrying the version of Dnmt3b mutated as in humans with
ICF1 are viable and show deregulated DNA methylation [15] (Box 3).
Patients with ICF1 harbor cytogenetic abnormalities affecting mainly chromosomes 1, 16,
and, to a lesser extent, 9, and the hypomethylation of juxtacentromeric repeats on these
chromosomes was identified before the discovery of DNMT3B as the ICF1-causing gene [16].
Patients with ICF1 present a targeted rather than global genome hypomethylation, leading to
chromatin decondensation and chromosome instability [13,17,18]. Chromosomes 1, 6, and 9
contain the longest blocks of satellite 2 and 3 tandem repeats adjacent to their centromeres
relative to other chromosomes; however, it is still unclear why the loss of the widely expressed
DNMT3B selectively affects specific repetitive sequences. It might be due to the subcellular
distribution or the context-specific protein interactions of DNMT3B [19], or that DNMT3B
activity is more important for the methylation of sequences with a high density of CpGs than
for other types of sequences, as observed for satellite 2 repeats [20]. In any case, chromatin
modification studies comparing B cell lymphoblastoid cell lines (LCLs) derived from patients
with ICF1 versus those from healthy controls showed that these cell lines present dysregu-
lation of genes involved in normal lymphocyte signaling, maturation, and migration, providing
a mechanistic link with the disease immunophenotype [11,21]. DNMT3B-dependentTrends in Immunology, January 2019, Vol. 40, No. 1 51
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Figure 1. General scheme of the main epigenetic regulatory mechanisms described in Boxes 1 and 2, and examples of their deregulation in human primary
immunodeficiencies (PIDs). (A) Post-translational modifications in histone tails. Lysine residues (K) on histone 3 (H3) tail are shown within the context of the nucleosome,
with their respective positions indicated (K4, 9, 27, or 36). The enzymes responsible for their methylation or demethylation are shown in blue, and the syndromes in
which these enzymes are defective are indicated in red (WS Wiedemann–Steiner syndrome; Kabuki syndrome; WHS: Wolf–Hirschhorn syndrome; and Kleefstra
syndrome). (B) Compacted nucleosomes and inaccessible chromatin. Nucleosome repositioning is required to access the DNA for transcription, and this is mediated by
chromatin remodelers (see Boxes 1 and 2). The ones that have been found altered so far in human immunodeficiencies are shown in blue inside the green arrow, and the
syndromes in which they are defective are indicated in red (CHARGE syndrome; ICF4: Immunodeficiency-Centromeric Instability Facial anomalies syndrome-4; SIOD:
Schimke immuno-osseous dysplasia: and INO80 loss-of-function). (C) Once nucleosomes have been repositioned, DNA is accessible to the transcription machinery
and RNA is synthesized. Correct splicing is essential for normal cellular function, and can be epigenetically regulated by noncoding RNAs, such as RNU4ATAC, which is
inactive in Roifman syndrome, therefore leading to serious defects. (D) At the level of DNA itself, the best studied epigenetic modification is cytosine methylation,
mediated by, among other enzymes (see Boxes 1 and 2) DNMT3B, which is mutated in Immunodeficiency-Centromeric Instability Facial anomalies-1 syndrome (ICF1).
Cytosine methylation can also be reverted in a process initiated by several enzymes, among them activation-induced cytidine deaminase protein (AID), inactivated in
Hyper-IgM syndrome 2 (HIGM2). The question mark close to AID indicates that the consequences of its ability to demethylate DNA are not yet fully understood.methylation changes in LCLs from patients with ICF1 have been correlated with a decrease in
the repressive H3K27m3 mark and an increase in the activating H3K9ac and H3K4m3 marks
relative to normal LCLs, leading to increased gene expression [21]. These results show that
the loss of DNMT3B function leads to hypomethylation of nonrepetitive regions of the genome52 Trends in Immunology, January 2019, Vol. 40, No. 1
Box 3. Animal Models of Altered Epigenetic Regulation
There are many published examples of immune malfunction and developmental alterations of the hematopoietic system
in different experimental models, mainly knockout mice, in which epigenetic regulators have been eliminated or
inactivated by mutation [98]. Mutations in epigenetic regulators can act as initiating oncogenic hits in many types
of human solid and hematopoietic tumor, and loss-of-function mouse models tend to recapitulate parts of the human
pathological phenotype, including aberrant hematopoietic differentiation [112]. Frequently, heterozygous or homo-
zygous full loss of function of epigenetic regulators leads to serious, even lethal, developmental defects, as an indication
of their essential role; this is clearly paralleled by the severity of phenotypes seen in human syndromes [113–115]. As
exemplified by mouse models of ICF1 syndrome (see main text), fully knocking out epigenetic regulators in mice might
point us towards the involvement of these genes in human pathologies. However, if alterations in these genes were to be
found in humans, they would most likely be hypomorphic (either exonic, regulatory, or hemizygous) rather than null,
since most of these genes are too important for embryonic development, and null mutations are probably incompatible
with life.and alterations in the histone code, also highlighting the interplay between DNA methylation
and other epigenetic modifications.
Besides the aforementioned transcriptional changes, DNA replication is also altered in
ICF1, either as a consequence of the alterations in the gene expression profile, or sec-
ondary to structural chromatin changes affecting the DNA replication machinery [22]. This
might also be correlated with ICF1-intrinsic chromosomal instability, but this remains to be
tested.
Approximately 40% of patients with ICF do not have mutations in DNMT3B, and constitute a
group called ‘ICF syndrome type 2’, presenting mutations in the ZBTB24 gene, which encodes
a transcriptional repressor involved in hematopoietic development [23]. ZBTB24 has a hyper-
methylated promoter in patients with ICF1 [24], suggesting that ZBTB24 malfunction is an
underlying mechanism accounting for the similar phenotypes seen in patients with ICF1 versus
those with ICF2. There is also an ICF3 subtype caused by mutation in the CDCA7 gene
(involved in HSC biology by a still as yet unclear mechanism) and an ICF4 type, caused by
mutation in the HELLS gene [encoding a chromatin-remodeling ATPase (Box 2) required for
correct DNA methylation] [25,26]. Since hypomorphic DNMT3B mutations are sufficient to
cause most cases of ICF1 [27], this syndrome is a paradigmatic example of how aberrant DNA
methylation can be involved in immunodeficiencies.
Immunodeficiencies due to Alterations in Histone Modifications
WHSC1 in Wolf–Hirschhorn Syndrome
WHS (OMIM 194190) is caused by the loss of genetic material in the ‘p’ arm of chromosome 4,
and is a contiguous gene syndrome [28]. Affected patients present with numerous defects,
including malformations, intellectual disabilities, and convulsions. They exhibit several degrees
of immunodeficiencies, including impaired antibody responses to T-independent antigens,
such as lipopolysaccharides, and deficiencies in IgA and IgG2 production, and also exhibit
CVID-like disease [29]. Among the genes affected by the 4p deletion, genotype/phenotype
correlation studies point to the hemizygous loss of the gene encoding Wolf–Hirschhorn
Syndrome Candidate-1 (WHSC1, also known as MMSET and NSD2) as the main cause for
malformations and immunodeficiencies [30]. WHSC1 is a large protein with histone H3 lysine 36
(H3K36) mono- and di-methyltransferase activity, known to act as an epigenetic regulator, as
shown by in vitro activity assays [31] and by in vivo studies using Whsc1-knockout mice [32]
(Box 2, Figure 1). Among many other modifications, histone 3 can be mono-, di- and
trimethylated in its Lysine-36. The H3K36m2 and H3K36m3 marks have been implicated in
many processes associated with basic genome-wide DNA biology, including transcriptionalTrends in Immunology, January 2019, Vol. 40, No. 1 53
elongation, DNA replication and repair, as well as establishing correct patterns of gene
expression [33,34].
Mouse Whsc1-knockout embryos die before birth or shortly thereafter [32]. Whsc1 was
recently shown to be essential for the normal differentiation and function of lymphocytes
[35]; in this study, both specification and commitment to the B cell lineage were impaired
in Whsc1–/– pro-B cells, as evidenced from competitive fetal liver transplantation experiments in
which normal numbers of Whsc1–/– progenitors were injected in a 1:1 ratio against wild-type
(WT) progenitors. Relative to WT controls, Whsc1–/– pro-B cells also exhibited significantly
reduced expression of transcription factors Ebf1 and Pax5, essential for specification and
commitment to the B cell lineage at the earliest stages of B cell development [35]. At later
stages, the second functional and developmental impairment of Whsc1–/–B cells was shown to
occur during germinal center (GC) formation, where class switch recombination (CSR), which
is necessary for the generation of new (switched) Ig isotypes, was significantly reduced relative
to WT controls. This was found to occur in a Whsc1-dose-dependent manner, since CSR was
more impaired in Whsc1–/– than in Whsc+/ cells and, in both those cell types, was more
impaired than in WT cells. This impairment was accompanied by aberrant proliferation of
Whsc1-deficient B cells, as measured by BrdU-incorporation cell cycle assays, caused, in turn,
by elevated replicative stress (determined by DNA fiber analysis) and by the accumulation of
DNA damage (as seen by increased levels of histone gH2AX incorporation) [35]. These findings
closely correlate with certain immunodeficiency patterns described in patients with WHS, with
defective production of switched Igs suggestive of CSR impairment [29], along with a DNA
replication impairment phenotype seen in immortalized cell lines derived from patient samples
[36]. Impaired development of Whsc1+/ lymphocytes has also been reported to gradually
increase with age, and this is clinically relevant because it may have important implications for
the long-term prognosis of immunodeficiency in patients with WHS [35]. This Whsc1 genetically
ablated mouse model provides an example of a preclinical model that can recapitulate certain
aspects of the immunodeficiency seen in humans.
KMT2D and KDM6A in Kabuki Syndrome
Kabuki syndrome (OMIM 147920) is a congenital disorder affecting many organs, and is
associated with a typical facial morphology, intellectual disability, skeletal abnormalities, and
immune deficiencies [37]. Exome-sequencing studies revealed that, in 52–76% of patients, the
pathology is due to mutations in the KMT2D gene (encoding the histone methyltransferase
Lysine-K-Methyltransferase 2D, also known as MLL2) [38] (Box 2 and Figure 1) that preferen-
tially mediates trimethylation of histone H3 lysine 4 (H3K4me3, a gene activation mark mainly in
charge of driving the transcription of constitutively expressed genes). Patients with Kabuki
syndrome lacking alterations in KMT2D can present mutations (three out of 32 patients
analyzed) in KDM6A [39], encoding a histone demethylase that removes mono-, di-, and
trimethyl groups from H3K27me3 (a repressive mark). Therefore, the two main genes involved
in Kabuki syndrome are part of the gene activation machinery, functioning to either add active
epigenetic marks or remove repressive ones, and, thus, affecting many downstream genes.
Nonetheless, the genetic basis of the syndrome remains unknown in 20–45% of patients [40].
Immune dysfunction is a common finding in Kabuki syndrome, since correct histone-3 meth-
ylation patterns are essential to achieving modifications in Ig genes required for B cell devel-
opment and function [41]. Approximately half of the patients present with CVID-like
characteristics, with decreased IgA levels, low total IgG levels, and some specific IgG subclass
abnormalities [42]. Relative to healthy individuals, the numbers of memory B cells are
reduced, with decreased levels of somatic hypermutation (SHM) in IgG (and, therefore,54 Trends in Immunology, January 2019, Vol. 40, No. 1
reduced antibody affinity) and, consequently, there is an inability to generate or maintain
specific antibody responses and long-term immunological memory [42]. Several patients
with Kabuki also present with autoimmune diseases, such as idiopathic thrombocytopenic
purpura (ITP), hemolytic anemia, thyroiditis, or vitiligo, although the frequency of autoimmune
conditions in this syndrome is unclear [43].
Finally, besides the originating mutations, and as a consequence of them, patients with Kabuki
syndrome present aberrant but syndrome-specific DNA methylation abnormalities, supporting
the existence of crosstalk between histone and DNA methylation systems that may be altered
by inborn errors of the epigenetic machinery [44,45].
EHMT1 in Kleefstra Syndrome
Kleefstra syndrome (OMIM 610253) is a neurodevelopmental disorder characterized by autism,
microcephaly, and dysmorphic features. Other complications, such as congenital heart and
urogenital defects and immunodeficiency, are also frequently observed [46]. Kleefstra syn-
drome is caused by haploinsufficiency of the gene encoding Euchromatin Histone Methyl-
transferase 1 (EHMT1, also known as G9a-Like Protein or GLP) [47]. Approximately 75% of
patients with Kleefstra syndrome have heterozygous microdeletions at chromosome 9q34.3,
whereas the remaining 25% have an intragenic EHMT1 pathogenic variant [48]. EHMT1,
together with its paralog G9a, mono- and dimethylates Lys-9 on histone H3 (H3K9me1
and H3K9me2) in euchromatin and, therefore, can promote heterochromatization and gene
repression [49]. The effects of deregulated H3K9 methylation manifest mainly at the level of the
nervous system in patients with Kleefstra syndrome, as evidenced by the mainly neurodeve-
lopmental nature of their defects, but they can affect the whole organism, although the way in
which they might interfere with immune functions remains unclear [50].
KMT2A in Wiedemann–Steiner Syndrome
Wiedemann–Steiner syndrome (OMIM 605130) is an autosomal dominant syndrome in which
patients present with a wide spectrum of alterations, including intellectual disability, develop-
mental delay, and immunodeficiency. It is caused in almost 100% of the identified cases by
heterozygous mutations in the KMT2A gene (encoding Lysine Methyltransferase 2A, also called
mixed-lineage leukemia, MLL) [51], encoding a H3K4 methyltransferase involved in hemato-
poiesis by governing the expression of key regulators, such as the HOX and WNT genes [52].
Several types of immune alterations have been described in patients with Wiedemann–Steiner
syndrome, including immunodeficiency accompanied by low concentrations of Igs, and fre-
quent urinary tract, respiratory, and ear infections [53]. In fact, PID resembling early-onset CVID
might be the first indication of Wiedemann–Steiner syndrome, despite nonimmunological
characteristics not yet being apparent [54].
Thus, WHS, Kabuki, Kleefstra, and Wiedemann–Steiner syndromes have been linked to altered
histone methylation patterns that can lead to defective antibody and Ig production in humans.
Immunodeficiencies due to Alterations in Chromatin Remodelers
SMARCAL1 in Schimke Immuno-Osseous Dysplasia
SIOD (OMIM 242900) is an autosomal recessive multisystem disorder characterized by bone
dysplasia, growth deficiency, defective cellular immunity, and progressive renal failure [55].
Patients are predisposed to viral and bacterial infections and present with decreased numbers
of CD4+ T cells in peripheral blood relative to healthy individuals [56]. Ex vivo, T cell proliferation
is impaired, and Ig levels are abnormal in two-thirds of patients, although B cell numbers are
normal [56].Trends in Immunology, January 2019, Vol. 40, No. 1 55
SIOD is caused by mutations in SMARCAL1 (encoding SWI/SNF-Related, Matrix Associ-
ated, Actin-Dependent  Regulator of Chromatin, Subfamily A Like 1) [57] (Figure 1), which
encodes an ATP-dependent DNA annealing helicase that maintains genomic integrity by
participating in DNA replication fork restart and DNA repair [58]. The IL7Ra promoter was
found to be hypermethylated in T cells from peripheral blood of patients with SIOD,
therefore diminishing IL-7 receptor alpha chain (IL7Ra) expression and rendering T cells
less responsive to IL-7, a stimulation pathway that is necessary for their development [59].
In human SIOD skin fibroblasts, as well as in Drosophila or mice defective in SMARCAL1
orthologs, there is an alteration in the expression of many genes (versus control WT cells);
however, in both mice and Drosophila, this alteration is insufficient to cause disease in the
absence of additional environmental or genetic insults [60]. This has led to the suggestion
that the incomplete penetrance of SIOD in humans is due to the fact that SMARCAL1
deficiency may need to be complemented by other genetic or environmental factors in
order to alter gene expression, and that the function of SMARCAL1 annealing helicase
activity is to maintain DNA topology in order to buffer variability in gene expression and, as a
result, diminish the penetrance of pathologic traits arising from environmental and genetic
insults [60].
INO80 in Class Switch Recombination Defects
Class-switch recombination defects (CSR-D) are rare PIDs characterized by impaired genera-
tion of switched immunoglobulin isotypes. CSR-Ds might be caused by impaired cooperation
between B and T cells or by several types of intrinsic B cell defects, which have not always been
identified [61]. Exome sequencing of two patients with CSR-D identified recessive, nonsynon-
ymous coding variations in the INO80 gene [61]. INO80 is the catalytic ATPase subunit of the
INO80 chromatin-remodeling complex (Box 2 and Figure 1) and participates in many processes
affecting DNA biology, including transcriptional regulation, DNA repair, and DNA replication
[62]. Enforced re-expression of WT INO80 in patient fibroblasts was found to correct cellular
hypersensitivity to g-irradiation [61]. Furthermore, in mouse B-lymphoid CH12-F3 cells, the
INO80 complex was shown to accumulate at switch regions of Ig loci and, in addition, INO80
downregulation via small hairpin (sh)RNA in the same cells led to impaired CSR, indicating that
INO80-mediated chromatin-remodeling activity was required for correct resolution of the CSR
process, probably at the level of DNA repair, although the potential mechanism remains to be
tested [62].
CHD7 in CHARGE Syndrome
CHARGE syndrome (OMIN 214800) is an autosomal dominant disorder characterized by
the conjunction of multiple birth defects (coloboma of the eye, heart defects, atresia of the
choanae, retardation of growth, genital and ear abnormalities). It presents a phenotypic
overlap with Kabuki and other immunodeficiency syndromes [63], and patients also
exhibit global changes in DNA methylation profiles [44]. However, CHARGE syndrome
is caused by loss-of-function mutations in the CHD7 gene, encoding a chromodomain
helicase DNA-binding protein, which is an ATP-dependent chromatin remodeler (refer to
Box 2 and Figure 1) [64]. CHD7 is the only gene currently known to be associated with
CHARGE syndrome, and pathogenic variants in this gene are found in 65–70% of
patients [65]. Patients with CHARGE can present with immunodeficiency, mainly associ-
ated with low peripheral T cell numbers (CD3+, CD4+, and/or CD8+ T cells) relative to
healthy individuals [66]; however, this is likely not due to a T cell-autonomous defect,
since thymic aplasia with severely reduced thymic function can be present in patients with
CHARGE; therefore, the main role of CHD7 malfunction in T cells remains to be
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Hence, together with SIOD and INO80 loss-of-function, CHARGE syndrome constitutes an
example of how alterations in proteins controlling chromatin remodeling can impact the
effectiveness of the immune system in affected patients.
Immunodeficiencies due to Alterations in Noncoding RNAs
Due to the heterogeneous nature and functions of noncoding (nc)RNAs (Boxes 1 and 2), the
recent identification of many of these, and the fact that a variety of important ncRNA subtypes
do not have bona fide epigenetic function, there are not many examples of these that have
been implicated in contributing to aberrant immune function in PIDs. However, Roifman
syndrome (OMIM 616651) falls into this class and provides a proof-of-principle of the
possibility that ncRNAs harbor an epigenetic function that can impact human immunodefi-
ciency. Roifman syndrome is an autosomal recessive disorder characterized by skeletal
dysplasia, immunodeficiency, retinal dystrophy, and developmental delay [67]. In all patients
studied so far, the syndrome is caused by compound heterozygous mutations in the small
nuclear RNA gene RNU4ATAC, necessary for U12-type intron splicing [68]. This mutation
disrupts correct intron splicing and leads to myriad alterations, including immunodeficiency
[54]. By analyzing the immune and hematopoietic systems of three patients with Roifman
syndrome from two unrelated kindreds with RNU4ATAC variants [69], specific splicing
defects in key genes (see later) were identified that might contribute to explaining the immune
phenotypes seen in patients. Indeed, patients with Roifman syndrome present a severe
reduction in peripheral, circulating B cell numbers, with a B cell differentiation block at the
transitional B cell stage compared with healthy individuals [69]. RNA-sequencing studies
identified a splicing defect in the gene encoding mitogen-activated protein kinase 1 (MAPK1)
[69]. Since MAPK1–MAPK3 heterodimers are required for survival signaling necessary for B
cell differentiation [70], this intrinsic defect might contribute to the observed phenotype,
although it does not exclude the presence of other B cell-intrinsic or extrinsic defects in
differentiation and survival caused by loss of function of RNU4ATAC and its associated minor
splicing complex [69].
Proteins with a Secondary Epigenetic Function Linked to Primary
Immunodeficiencies
Recent research focusing on altered proteins in immunodeficiencies has identified new molec-
ular functions for these proteins. These findings might provide new insights into immune
dysfunction in certain PIDs, the molecular mechanisms of which were originally thought to
be independent of any epigenetic modifications.
WASP in Wiskott-Aldrich Syndrome
One clear example is Wiskott-Aldrich syndrome (WAS, OMIM 301000), an X-linked disorder
characterized by microthrombocytopenia, eczema, and recurrent infections [71]. WAS is
caused by mutations affecting the WAS protein (WASP), the main function of which is to relay
signals from the surface of the cell to the actin cytoskeleton. WASP deficiency results in
significant abnormalities of T-lymphocyte numbers and function [72]; T cells from patients with
WAS present an absent or impaired function of WASP, along with impaired T cell differentiation
and a decreased ability to be activated and to respond to the environment, relative to controls
[71]. However, besides its cytoplasmic function, WASP also has nuclear activity and is capable
of modulating the expression of the TBX21 gene [73]. TBX21 (or T-Bet: T-box protein
expressed in T cells) was originally described as a transcription factor essential for the
commitment of T helper (Th) cells to the Th1 lineage, by directly activating the transcription
of the gene encoding IFN-g [74]. At the same time, TBX21 modulates Th2 cytokines to result in
decreased Th2 development [74]. Later studies reported that TBX21 has multiple roles in manyTrends in Immunology, January 2019, Vol. 40, No. 1 57
other immune cell types, including B cells, dendritic cells, and natural killer (NK) cells, and,
therefore, is deemed essential for the development and coordination of both innate and
adaptive immune responses [75]. In WAS, WASP modulates the expression of TBX21 by
associating with H3K4 methyltransferase RBBP5 and H3K9/H3K36 demethylase JMJD2A, the
enzymatic activities of which are required for activating chromatin at the TBX21 proximal
promoter [73], supporting the existence of a nuclear mechanism underlying deregulated T cell
immunity in human WAS.
AID in immunodeficiency syndrome with hyper-IgM, type 2
Another example of a protein with an epigenetic role ‘additional’ to its main function is that
of activation-induced cytidine deaminase protein (AID). AID can catalyze cytosine-to-uracil
deaminations on single-stranded DNA mainly at genes encoding Igs during the GC reac-
tion, creating U:G mismatches that, when repaired by different means, can lead to CSR and
SHM [76,77]. Accordingly, inactivating AID mutations cause immunodeficiency syndrome
with hyper-IgM, type 2 (HIGM2) (OMIM 605258) [78]; patients with HIGM2 are susceptible
to bacterial infections because their B cells cannot perform CSR and SHM [78]. However,
AID, harboring deaminase activity, when acting on methylated cytosines, can also lead to
effective DNA demethylation [79] and, therefore, might have a role in the demethylation of
specific loci and the activation of specific genes relevant in immunodeficiencies (reviewed in
[80]). It is clear that the phenotype of patients with HIGM2 is primarily due to an impaired
production of switched and hypermutated antibodies; nonetheless, mouse Aid can regulate
DNA methylation in HSCs as well as during myeloid/erythroid differentiation, and Aid loss in
knockout mice leads to myeloid cell expansion and reduction in the numbers of erythroid
progenitors, with dysregulated expression of Cebpa and Gata1, encoding key myeloid/
erythroid lineage-specific transcription factors [81]. Similarly, shRNA-mediated knockdown
of AID in human bone marrow cells skews their differentiation toward the myelomonocytic
lineage [81]. During reprogramming of primary mouse embryonic fibroblast (MEF) to
induced pluripotent stem cells, bisulfite genome-wide analysis of DNA demethylation
showed that reprogramming appears to require Aid-mediated downregulation of Uhrf1
protein, an essential component of the DNA methylation maintenance machinery, although
this appears to be independent on Aid deaminase activity [82]. In addition, AID has been
shown to be a driver of epigenetic heterogeneity in B cell lymphomas, since ectopic Aid
overexpression causes more aggressive disease in Bcl2-driven murine lymphomas, and
this phenotype is not associated with increased Aid-mediated somatic mutation, but with
elevated cytosine methylation heterogeneity [83]. Therefore, through some of the afore-
mentioned mechanisms and/or others still unknown, a potential (albeit accessory) AID-
mediated epigenetic component in patients with HIGM2 may be significant and cannot be
completely discarded.
Epigenetic Alterations without a Known Genetic Origin in Human
Immunodeficiency
Epigenetic modifications can be changed (reprogrammed) in response to either internal or
environmental stimuli in the absence of genetic mutations. This can happen, as in the case of
lymphocyte development, in the context of normal cellular differentiation and, even more, it is in
fact necessary for the definition of cellular identity [6]. However, epigenetic reprogramming can
also be triggered by environmental exposures [10], and the altered epigenetic patterns can be
self-perpetuating. From studies in cancer biology, we have learned that epigenetic alterations
have an essential role in the origin and evolution of most types of tumor; for many years, only
bona fide genetic mutations affecting the DNA sequence were considered important as
molecular culprits behind cancer origin or progression [8,84]. However, we now know that58 Trends in Immunology, January 2019, Vol. 40, No. 1
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Potential Roles for Epigenetic Priming in Human Immunodeficiencies. Although the underlying
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epigenetic reprogramming is an essential part of tumor pathogenesis and maintenance [9,85].
Furthermore, it is known that even the earliest stages of tumor initiation can almost fully be
epigenetically mediated [86–89].
The findings that we have described above open the possibility of delineating a parallel
picture for our understanding of a subset of human PIDs (Figure 2), where epigenetic
alterations are involved in the development and/or evolution of PIDs. We have seen that
different types of alteration in essential epigenetic regulators can cause severe malfunc-
tions of the immune system, although the specific mechanisms can vary among diseases,
and many remain unknown. In addition, we have provided examples of how proteins with
well-established activities can also have epigenetic functions that might be important in
immunodeficiencies. The application of next-generation sequencing (NGS) techniques is
allowing the diagnosis of new cases and the identification of new genes involved in
immunodeficiencies [90]. Nevertheless, there are many cases where causative mutations
cannot be identified [90,91]. In fact, for the most frequent type of PIDs, CVID, NGS
approaches have only identified potentially disease-causing mutations in 30–65% of
patients [92,93]. These percentages have led to the conclusion that a significant proportion
of CVIDs might be due to polygenic causes, in which the combination of many genetic
variants can lead to the appearance of different immunodeficiencies of variable character-
istics [91,94–96].
By analogy with cancer, a step further takes us to the additional, nonexcluding, possibility of the
existence of epigenetic anomalies that condition or prime the development of PIDs, and do not
have their origin in genetic mutations of epigenetic regulatory genes, but are in fact triggered by
internal or environmental reprogramming events (Figure 2). Along these lines, in a recent study,
high-throughput DNA methylation analyses in monozygotic twins discordant for CVID revealed
a gain of DNA methylation in affected B cells compared with those from a healthy sibling [97]. A
confirmatory study in a cohort of sporadic CVID cases revealed that critical B cell genes, such
as PIK3CD, BCL2L1, RPS6KB2, TCF3, or KCNN4, showed an impaired capacity for deme-
thylating and upregulating their transcriptional expression in B cell transition from naive to
memory cells in CIVD [97]. These results, together with data from knockout mice (Box 3 [98])
and other reports discussed in this review, lead us to propose that a fully epigenetic mechanism
might contribute to explaining the origin of certain subsets of human immunodeficiencies
(Figure 2).epigenetic mechanism initially altered might vary (DNA methylation, histone modifications, or chromatin remodeling), its
involvement in the immunodeficiency pathology can follow a series of similar steps. (A) A defined genetic mutation
inactivates a given epigenetic regulator (or a protein with an indirect epigenetic effect). This leads to epigenetic repro-
gramming that modifies the pattern of gene expression of the affected cells and, therefore, their development and/or
function. If the penetrance of the phenotype associated with this mutation and/or syndrome is high, then the appearance of
the immunodeficiency is just a matter of time (variable depending on the disease). If the penetrance is lower, then the
appearance of the immunodeficiency may be conditioned by other modifying genes or by environmental exposures
(infections or other agents, see later). (B) In the absence of a defined genetic mutation, the combination of specific gene
variants might prime the epigenomes of certain individuals and make them more susceptible to external agents that might
trigger immunodeficiency. This dependence on external factors could explain the differences found in identical twins.
(C) Conversely, this combination of specific gene variants might make the individual more susceptible to changes caused
by external agents, and these changes can in turn lead to an epigenetic priming that ultimately causes immunodeficiency.
(D) Finally, in a ‘completely healthy’ individual, exposure to environmental factors in early life (pathogens, radiation,
chemicals, etc.) might trigger epigenetic changes that render this individual more susceptible to exposure to external or
endogenous agents later in life, which will trigger immunodeficiency.
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Translational Implications of Epigenetic Reprogramming in PIDs
The existence of epigenetic deregulation as a proposed mechanism of pathogenesis in certain
PIDs might have diagnostic, prognostic, prophylactic, and even therapeutic implications for
clinical management (Figure 3). On the one hand, epigenetic modifications can be triggered by
exposure to many different environmental agents (chemicals, radiation, infections, our own
microbiome, etc.) and also by endogenous causes, such as exercise or aging [99]. The immuneCongenital
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Figure 3. Prophylactic and Therapeutic Implications of Epigenetic Modulation in Immunodeficiencies. (A) An
inactivating mutation could be corrected by using some of the diverse existing gene therapy approaches. The alternative
would be to revert the pathological epigenetic priming and restore normal physiological cellular development and function.
Proof-of-principle experiments in animal models will have to demonstrate whether aberrant epigenetic reprogramming can
be reverted to normal conditions in vivo, something that likely varies among diseases. Afterwards, either highly specific
epigenetic drugs or targeted gene therapy would be required to guide therapeutic reprogramming. (B) In the context of
susceptibility, the first key aspect would be the diagnosis and identification of such predisposition, something that is still in
its infancy in most cases. Once an individual has been found to be susceptible to a certain disease or to a certain exposure,
then prophylactic measures might be undertaken to avoid such exposure. Alternatively or complementarily, epigenetic
therapies would need to be established to potentially prevent or to revert pathological reprogramming. (C) Finally, if specific
exposures at defined developmental points are shown to promote immunodeficiency in healthy, nonsusceptible indivi-
duals, then preventive measures might be implemented to avoid such consequences. Again, alternatively or comple-
mentarily, epigenetic therapies might be established to putatively prevent or to revert pathological reprogramming.
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Outstanding Questions
To what extent are PIDs of genetic
origin only? Can environmental (exog-
enous or endogenous) exposure be a
trigger of an underlying hidden (epi)
genetic condition? If so, what is the
contribution of each exposure type
to the development of disease?
Can we identify hypomorphic but non-
lethal mutations in (epi)genetic regula-
tors that are responsible for
immunodeficiencies? Can we distin-
guish them from normal variants?
Can they act alone, or do they require
collaborating variants and/or
mutations?
In the absence of obvious germline or
somatic mutations, can we identify
genetic associations of polymor-
phisms indicating predisposition to
specific PIDs? Can we identify the
main genetic contributors to specific
PIDs? Can we stratify the population
according to polygenic risk scores?
Will it be possible to implement effec-
tive prophylactic measures to prevent
or delay the appearance of symptoms
in susceptible individuals?
How can we generate faithful animal
models reflecting all the complexity of
human PIDs? Can proof-of-principle
experiments performed in such mod-
els be translated to humans? Will these
models be good proxies to study the
role of environmental exposure in the
development of PIDs?
Can epigenetic alterations associated
with PIDs be reverted once they have
already been established? Could this
be done pharmacologically, or are
more complex gene therapy
approaches required? What will the
developmental and cellular windows
for therapeutic intervention be?system, by its very nature, is especially sensitive to environmental exposures (which, in
instances such as chemotherapy, radiation, HIV infection, or pesticides, can be associated
with, or causal to, secondary immunodeficiencies that are not genetic in origin), triggering
abnormalities, such as leukemia and autoimmunity, the etiology of which has been linked to
clear epigenetic regulation [9,100–102]. A deeper knowledge of the precise epigenetic mech-
anisms by which such exposures might contribute to the appearance of certain PIDs might
allow the future exploration of approaches aimed at recovering potential developmental or
functional immune cell impairment (Figure 3). Numerous questions remain (see Outstanding
Questions), and extensive, robust testing will be required to address these.
The potentially polygenic origin of still unidentified PIDs might render some patients more
susceptible to epigenetic reprogramming of their immune system as a response to certain
stimuli (e.g., infections, medication, or malnutrition). Moreover, the identification of variants or
SNPs associated with such susceptibilities might allow a putative prognostic evaluation, or
clinical and analytical follow-up, in individuals at risk for developing a PID disease with full
penetrance (see Outstanding Questions).
Concluding Remarks
The only curative procedure for severe and life-threatening PIDs so far is the correction of the
gene defect in HSCs, either by transplantation of allogenic donor-derived cells or the correction
of autologous stem cells by gene therapy. Predominantly, antibody deficiencies affecting the B
cell differentiation and maturation without a severe combined T cell defect are not suitable for
HSCT due to severe complications still inherent to the procedure, such as infections and graft
versus host disease (GvHD) [103,104]. In addition, gene therapy developments are under-
standably mostly focused on severe PIDs. When a genetic defect interferes to some degree
with embryonic development (especially in syndromic immunodeficiencies), alterations in
morphogenesis and organogenesis, even if compatible with life, are in most cases irreversible
with current technology. However, some of the functional defects specific to a given cellular
type, or those affecting systems in which morphogenesis is not so important for function (e.g.,
the immune system), might be amenable to correction using appropriate strategies in the right
time window [105,106]. Evidently, these tests will have to be first performed as proof-of-
principle experiments in animal models, and their translation to the clinic will be slow and difficult
(see Outstanding Questions). However, it will be important to ascertain the degree of revers-
ibility (if any) to a normal developmental epigenome along the different stages of cellular
differentiation in animal models and in certain immunodeficient patients. Indeed, for some
subgroups of PIDs, epigenetic modifiers with a potential role in reversing the cellular defects
could constitute the first ‘curative’ possibility. Therefore, we need to better understand the
molecular underpinnings of the persistence of an aberrant epigenetic pattern in immunode-
ficiencies to explore the possible potential of reversion to a normal, or less dysfunctional, profile.
In experimental systems, certain cancer cells can be reprogrammed back to nontumoral fates,
losing their malignant status via administration of epigenetic drugs, or by means of gene
reprogramming [9]. Therefore, it is conceivable that either epigenetic drugs or gene therapy
approaches targeted in the right cellular compartments and during the right developmental
stage might lead to the reversion of the immunodeficient epigenetic program to a normal,
functional one. Potential future epigenetic drugs might be similar to existing drugs, acting in a
more or less genome-wide manner over a given epigenetic mark, or might be newly developed
targeted epigenetic modifiers capable of altering epigenetic marks, not in a global way, but
rather, in a more precise location-specific manner; this might be achieved by the use of different
(epi)genome-editing tools, including zinc finger proteins, transcription activator-like effectors
(TALEs), or the CRISPR-Cas9 system [107].62 Trends in Immunology, January 2019, Vol. 40, No. 1
Finally, there are other pathologies of immune cells with a strong epigenetic component,
including, for example, leukemias, certain autoimmune disorders, or viral infections (where
viruses often hijack the epigenetic mechanisms of the immune cell to subvert immune function)
[108]. Therefore, we anticipate that therapeutic advances obtained studying the epigenetics of
immunodeficiencies might be applicable to other pathologies, and vice versa. It will be
remarkable to follow these advances in the years to come.
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